References
- Alving BM. The hypercoagulable states. Hosp Pract 1993; 28(2): 109–14, 119–21
- Tabernero MD, Toraas JF, Alberca I, et al. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36(4): 249–54
- Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74(1): 94–100
- Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330(8): 517–22
- Bauer KA. Hypercoagulability—a new cofactor in the protein C anticoagulant pathway. (Editorial) N Engl J Med 1994; 330(8): 566–7
- Griffin JH, Evatt B, Wideman C, et al. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82(7): 1989–93
- Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III-deficient persons: report of a large kindred and literature review. Ann Intern Med 1992; 116(9): 754–61
- Bovili EG, Bauer KA, Dickerman JD, et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73(3): 712–7
- Engesser L, Broekmans AW, Briet E, et al. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106(5): 677–82
- Heijboer H, Brandjes DP, Buller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323(22): 1512–6
- Devine DV, Brigden ML. The antiphospholipid syndrome: when does the presence of antiphospholipid antibodies require therapy? Postgrad Med 1996; 99(6): 105–8, 113–25
- Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317(16): 991–6
- Koeleman BP, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84(4): 1031–5
- van Boven HH, Reitsma PH, Rosendaal FR, et al. Interaction of factor V Leiden with inherited antithrombin deficiency. Thromb Haemost 1995; 73: 1256
- Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. J Clin Invest 1994; 94: 923
- Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344(8935): 1453–7
- Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173(1): 210–3
- The Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74(4): 1185–90
- Schramm W, Spannagl M, Bauer KA, et al. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993; 129(6): 753–6
- Goodwin TM, Gazit G, Gordon EM. Heterozygous protein C deficiency presenting as severe protein C deficiency and peripartum thrombosis: successful treatment with protein C concentrate. Obstet Gynecol 1995; 86(4 Pt 2): 662–4
- Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332(15): 993–7
- Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 1994; 71(1): 15–8
- Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335(2): 108–14
- Menache D. Antithrombin III concentrates. Hematol Oncol Clin North Am 1992; 6(5): 1115–20